Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.33 |
| ▸ | CTSB | P07858 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11076258 | 0.98 | TP53 (0.53) | TP53POLBLMNANOTUMPTGDR2 | |
| SCHEMBL11066272 | 0.84 | TP53 (0.51) | TP53POLBLMNANOTUMKDM4E | |
| SCHEMBL23498885 | 0.83 | TP53 (0.49) | TP53POLBLMNANOTUMKDM4E | |
| SCHEMBL7678717 | 0.82 | LMNA (0.57) | TP53POLBLMNAKDM4EL3MBTL1 | |
| SCHEMBL11241475 | 0.79 | TP53 (0.37) | TP53POLBLMNAKDM4EALDH1A1 | |
| SCHEMBL11214797 | 0.78 | PTGS2 (0.54) | TP53POLBLMNAALDH1A1 | |
| SCHEMBL23498965 | 0.76 | TP53 (0.44) | TP53POLBLMNANOTUMKDM4E | |
| SCHEMBL9959156 | 0.74 | TP53 (0.40) | TP53POLBLMNANOTUMKDM4E | |
| SCHEMBL5553127 | 0.72 | TP53 (0.39) | TP53POLBLMNANOTUMKDM4E | |
| SCHEMBL21810001 | 0.71 | TP53 (0.43) | TP53POLBLMNANOTUMKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105214-B2 | Recording sheets containing pyrrole, pyrrolidine, pyridine, piperidine, homopiperidine, quinoline, isoquinoline, quinuclidine, indole, and indazole compounds | XEROX CORPORATION (US) | 2006-09-12 | — | — | US | claimed |
| US-20030124320-A1 | Recording sheets containing pyrrole, pyrrolidine, pyridine, piperidine, homopiperidine, quinoline, isoquinoline, quinuclidine, indole, and indazole compounds | XEROX CORPORATION | 2003-07-03 | — | — | US | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0673782-B1 | Recording sheets containing pyrrole, pyrrolidine, pyridine, piperidine, homopiperidine, quinoline, isoquinoline, quinuclidine, indole, and indazole compounds | XEROX CORP (US) | 2000-06-14 | — | — | EP | claimed |
| US-5657064-A | Recording sheets containing pyrrole, pyrrolidine, pyridine, piperidine, homopiperidine, quinoline, isoquinoline, quinuclidine, indole, and indazole compounds | XEROX CORPORATION (US) | 1997-08-12 | — | — | US | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| EP-0673782-A2 | Recording sheets containing pyrrole, pyrrolidine, pyridine, piperidine, homopiperidine, quinoline, isoquinoline, quinuclidine, indole, and indazole compounds | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | claimed |
| EP-0092487-B1 | PROCESS FOR THE PREPARATION OF 3-CARBOXY-1,4-DIMETHYLPYRROL-2-ACETIC ACID | Montedison S.p.A. (IT) | 1987-10-07 | — | — | EP | claimed |
| EP-0092487-A1 | Process for the preparation of 3-carboxy-1,4-dimethylpyrrol-2-acetic acid | Montedison S.p.A. (IT) | 1983-10-26 | — | — | EP | claimed |
| US-4363918-A | Method of preparing 1-alkyl-3-carboxy-1H pyrrole-2-acetic acids | JANSSEN PHARMACEUTICA N.V. (BE) | 1982-12-14 | — | — | US | claimed |
| US-8304406-B2 | Compounds for treating pulmonary hypertension | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-8304406-B2 | Compounds for treating pulmonary hypertension | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-11-06 | — | — | US | disclosed |
| US-20110263597-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER HEALTHCARE LLC (US) | 2011-10-27 | — | — | US | disclosed |
| WO-1982001552-A1 | PROCESS FOR PRODUCING SUBSTITUTED PYRROLES | ETHYL CORP (US) | 1982-05-13 | — | — | WO | disclosed |
| EP-0051442-A1 | Process for producing substituted pyrroles | ETHYL CORPORATION (US) | 1982-05-12 | — | — | EP | disclosed |
| US-3952012-A | MULTISTAGE | MCNEIL LABORATORIES, INCORPORATED (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263597-A1 | SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY | VEGFA, PGF, FLT1 | TP53 1473/4885POLB 1104/4885LMNA 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.